Kuraray Medical Transfers Apheresis Business Rights To Kuwasumi Laboratories
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based Kuraray Medical agreed to transfer therapeutic apheresis device business rights to Kuwasumi Laboratories this October. The company also plans to transfer the apheresis device manufacturing business to Asahi Chemical Kuraray Medical. The original plan to transfer the whole business to Asahi Chemical was blocked by the Japan Fair Trade Commission in 2006. Kuraray said the negotiation with Asahi Chemical is still undergoing. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.